Within the Campus ALL network we analyzed the incidence, characteristics, treatment and outcome of a central nervous system (CNS) relapse in 1035 consecutive adult acute lymphoblastic leukemia (ALL) patients treated frontline with pediatric-inspired protocols between 2009 and 2020. Seventy-one patients (6.8%) experienced a CNS recurrence, more frequently in T- (28/278; 10%) than in B-ALL (43/757; 5.7%) (p = 0.017). An early CNS relapse—< 12 months from diagnosis—was observed in 41 patients. In multivariate analysis, risk factors for early CNS relapse included T-cell phenotype (p = <0.001), hyperleucocytosis >100 × 109/L (p<0.001) and male gender (p = 0.015). Treatment was heterogeneous, including chemotherapy, radiotherapy, intrathecal therapy and novel agents. A complete remission (CR) was obtained in 39 patients (55%) with no differences among strategies. After CR, 26 patients underwent an allogenic transplant, with a significant overall survival benefit compared to non-transplanted patients (p = 0.012). After a median observation of 8 months from CNS relapse, 23 patients (32%) were alive. In multivariate analysis, the time to CNS relapse was the strongest predictor of a lower 2-year post-relapse survival (p<0.001). In conclusion, in adult ALL the outcome after a CNS relapse remains very poor. Effective CNS prophylaxis remains the best approach and allogenic transplant should be pursued when possible.

Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study / Dargenio, M.; Bonifacio, M.; Chiaretti, S.; Vitale, A.; Fracchiolla, N. S.; Papayannidis, C.; Giglio, F.; Salutari, P.; Audisio, E.; Scappini, B.; Zappasodi, P.; Defina, M.; Forghieri, F.; Scattolin, A. M.; Todisco, E.; Lunghi, M.; Guolo, F.; Del Principe, M. I.; Annunziata, M.; Lazzarotto, D.; Cedrone, M.; Pasciolla, C.; Imovilli, A.; Tanasi, I.; Trappolini, S.; Cerrano, M.; La Starza, R.; Krampera, M.; Di Renzo, N.; Candoni, A.; Pizzolo, G.; Ferrara, F.; Foa, R.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - (2022), pp. 1-8. [10.1111/bjh.18537]

Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study

Candoni A.;
2022

Abstract

Within the Campus ALL network we analyzed the incidence, characteristics, treatment and outcome of a central nervous system (CNS) relapse in 1035 consecutive adult acute lymphoblastic leukemia (ALL) patients treated frontline with pediatric-inspired protocols between 2009 and 2020. Seventy-one patients (6.8%) experienced a CNS recurrence, more frequently in T- (28/278; 10%) than in B-ALL (43/757; 5.7%) (p = 0.017). An early CNS relapse—< 12 months from diagnosis—was observed in 41 patients. In multivariate analysis, risk factors for early CNS relapse included T-cell phenotype (p = <0.001), hyperleucocytosis >100 × 109/L (p<0.001) and male gender (p = 0.015). Treatment was heterogeneous, including chemotherapy, radiotherapy, intrathecal therapy and novel agents. A complete remission (CR) was obtained in 39 patients (55%) with no differences among strategies. After CR, 26 patients underwent an allogenic transplant, with a significant overall survival benefit compared to non-transplanted patients (p = 0.012). After a median observation of 8 months from CNS relapse, 23 patients (32%) were alive. In multivariate analysis, the time to CNS relapse was the strongest predictor of a lower 2-year post-relapse survival (p<0.001). In conclusion, in adult ALL the outcome after a CNS relapse remains very poor. Effective CNS prophylaxis remains the best approach and allogenic transplant should be pursued when possible.
2022
1
8
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study / Dargenio, M.; Bonifacio, M.; Chiaretti, S.; Vitale, A.; Fracchiolla, N. S.; Papayannidis, C.; Giglio, F.; Salutari, P.; Audisio, E.; Scappini, B.; Zappasodi, P.; Defina, M.; Forghieri, F.; Scattolin, A. M.; Todisco, E.; Lunghi, M.; Guolo, F.; Del Principe, M. I.; Annunziata, M.; Lazzarotto, D.; Cedrone, M.; Pasciolla, C.; Imovilli, A.; Tanasi, I.; Trappolini, S.; Cerrano, M.; La Starza, R.; Krampera, M.; Di Renzo, N.; Candoni, A.; Pizzolo, G.; Ferrara, F.; Foa, R.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - (2022), pp. 1-8. [10.1111/bjh.18537]
Dargenio, M.; Bonifacio, M.; Chiaretti, S.; Vitale, A.; Fracchiolla, N. S.; Papayannidis, C.; Giglio, F.; Salutari, P.; Audisio, E.; Scappini, B.; Zap...espandi
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2022 - Dargenio - Incidence treatment and outcome of central nervous system relapse in adult acute.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 803.16 kB
Formato Adobe PDF
803.16 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294057
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact